Literature DB >> 10871348

Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA.

A Janz1, C Sevignani, K Kenyon, C V Ngo, A Thomas-Tikhonenko.   

Abstract

The Myc oncoprotein is implicated in transcriptional regulation of a variety of genes pertaining to cell cycle and neoplastic transformation. Examples of both positive and negative regulation have been reported that involve E-box and initiator (Inr) promoter elements, respectively. In both cases, Myc is thought to induce changes in transcription initiation. We have previously shown that overexpression of Myc causes down-regulation of the thrombospondin-1 (tsp-1) gene, an important negative modulator of tumor angiogenesis. In this study, we demonstrate that Myc in combination with Max can bind, albeit with low affinity, to an E-box-like element in the tsp-1 promoter. However, the 2.7 kb DNA segment containing both this non-canonical E-box and an Inr-like sequence does not constitute a Myc-responsive element in a transient expression system. Furthermore, Myc does not significantly affect the rate of initiation or elongation of the tsp-1 mRNA. Thus, in this instance Myc does not act as a canonical transcription factor. Instead, as demonstrated by blocking de novo RNA synthesis, down-regulation of the tsp-1 gene by Myc occurs through increased mRNA turnover. To our knowledge, this is the first example of gene regulation by Myc that involves mRNA destabilization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871348      PMCID: PMC102633          DOI: 10.1093/nar/28.11.2268

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  50 in total

1.  Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro.

Authors:  M L Iruela-Arispe; P Bornstein; H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

2.  Translational control of human cytomegalovirus gp48 expression.

Authors:  M R Schleiss; C R Degnin; A P Geballe
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Overproduction of v-Myc in the nucleus and its excess over Max are not required for avian fibroblast transformation.

Authors:  A T Tikhonenko; A R Hartman; M L Linial
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

4.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Authors:  D J Good; P J Polverini; F Rastinejad; M M Le Beau; R S Lemons; W A Frazier; N P Bouck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Negative autoregulation of c-myc transcription.

Authors:  L J Penn; M W Brooks; E M Laufer; H Land
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

6.  Characterization of the mouse thrombospondin 2 gene.

Authors:  T Shingu; P Bornstein
Journal:  Genomics       Date:  1993-04       Impact factor: 5.736

7.  An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro.

Authors:  G Brewer
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

8.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.

Authors:  B Amati; S Dalton; M W Brooks; T D Littlewood; G I Evan; H Land
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

9.  Myc and Max proteins possess distinct transcriptional activities.

Authors:  L Kretzner; E M Blackwood; R N Eisenman
Journal:  Nature       Date:  1992-10-01       Impact factor: 49.962

10.  Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region.

Authors:  G C Prendergast; E B Ziff
Journal:  Science       Date:  1991-01-11       Impact factor: 47.728

View more
  31 in total

1.  Thrombospondins: from structure to therapeutics.

Authors:  D D Roberts
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

2.  Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster.

Authors:  Michael Dews; Asal Homayouni; Duonan Yu; Danielle Murphy; Cinzia Sevignani; Erik Wentzel; Emma E Furth; William M Lee; Greg H Enders; Joshua T Mendell; Andrei Thomas-Tikhonenko
Journal:  Nat Genet       Date:  2006-07-30       Impact factor: 38.330

3.  Decreased astrocytic thrombospondin-1 secretion after chronic ammonia treatment reduces the level of synaptic proteins: in vitro and in vivo studies.

Authors:  Arumugam R Jayakumar; Xiao Y Tong; Kevin M Curtis; Roberto Ruiz-Cordero; Nagarajarao Shamaladevi; Missa Abuzamel; Joshua Johnstone; Gabriel Gaidosh; Kakulavarapu V Rama Rao; Michael D Norenberg
Journal:  J Neurochem       Date:  2014-08-01       Impact factor: 5.372

Review 4.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

5.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 6.  Differential expression of microRNAs in different disease states.

Authors:  Maha Abdellatif
Journal:  Circ Res       Date:  2012-02-17       Impact factor: 17.367

7.  HIF-1α represses the expression of the angiogenesis inhibitor thrombospondin-2.

Authors:  Susan C MacLauchlan; Nicole E Calabro; Yan Huang; Meenakshi Krishna; Tara Bancroft; Tanuj Sharma; Jun Yu; William C Sessa; Frank Giordano; Themis R Kyriakides
Journal:  Matrix Biol       Date:  2017-08-05       Impact factor: 11.583

8.  Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Authors:  Sylvie Giuriato; Sandra Ryeom; Alice C Fan; Pavan Bachireddy; Ryan C Lynch; Matthew J Rioth; Jan van Riggelen; Andrew M Kopelman; Emmanuelle Passegué; Flora Tang; Judah Folkman; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-20       Impact factor: 11.205

Review 9.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 10.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.